Apoptosis‐Sensitizing Tumor Nanomedicine by Regulating Pyroptosis‐Associated Inflammatory Cell Death

Author:

Du Fangxue1,Zhao Hongxin1,Song Yangmeihui2,Feng Ziyan1,Liu Kai3,Wang Ziyao1,Guo Ruiqian1,Qiu Li1,Chen Qiqing4,Zhou Liqiang5ORCID

Affiliation:

1. Department of Ultrasound West China Hospital Sichuan University Chengdu 610041 China

2. Department of Nuclear Medicine Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

3. Department of Cardiology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China

4. Department of Ultrasound Hainan General Hospital Hainan Affiliated Hospital of Hainan Medical University Haikou 570311 China

5. MOE Frontiers Science Center for Precision Oncology Faculty of Health Sciences University of Macau Macau SAR 999078 China

Abstract

AbstractThe vigorous development of cancer nanomedicine has revolutionized traditional oncology medicine, but it is also limited by the continuous mutation of cunning cancer cells, leading to apoptosis insensitivity and therapeutic disappointment. Inflammatory‐regulated cell death (RCD), especially pyroptosis‐related cell death, demonstrates huge potential for apoptosis sensitization due to its unique biochemical characteristics. The aim of this research is to present a thorough synopsis of the current knowledge on pyroptosis‐associated inflammatory cell death, including pyroptosis, cuproptosis, and PANoptosis, and the synergistic function in cancer nano therapy. Paradigm studies of pyroptosis‐related cell death‐mediated apoptosis‐sensitizing tumor nanotherapeutics are introduced in detail, and the coordination mechanisms based on nanomaterials are also discussed. In addition, multi‐angle analysis of the future prospects of pyroptosis‐sensitized tumor nanomedicine based on various nanomaterials is also emphasized to further expand the application scope of inflammatory RCD. It is believed that emerging auxiliary apoptosis‐sensitizing treatments based on inflammatory RCD will greatly promote the progress of cancer nanomedicine.

Funder

National Natural Science Foundation of China

Fundo para o Desenvolvimento das Ciências e da Tecnologia

Universidade de Macau

Sichuan Province Science and Technology Support Program

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3